30 November 2005 – Leading cell therapy company CyGenics Limited (ASX: CYN) announced today that its wholly-owned subsidiary, Cell Sciences Ltd, has entered into a non-exclusive distribution agreement with CombiMatrix group of Acacia Research Corporation (Nasdaq: CBMX:ACTG), to distribute CombiMatrix products and services in Singapore.
Under the terms of the agreement, Cell Sciences will market and sell CustomArrays™, CatalogArrays™ and CustomArray Synthesizers, which are semiconductor-based tools for use in identifying and determining the roles of genes, and the recently introduced Influenza Research Microarray, to the Southeast Asian market.
“We are very pleased to have expanded our distribution network into Southeast Asia,” said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. “I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share.”
“Cell Sciences has identified CombiMatrix’s platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology,” said Mr Steven Fang, Group CEO, CyGenics. “This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship.”
About Cell Sciences
Cell Sciences is a subsidiary of CyGenics which is listed in the Australian Stock Exchange (ASX). It has an established network covering Singapore, Malaysia, Thailand, Indonesia, Philippines, Hong Kong, China, Australia and USA. Cell Sciences is a supplier of diagnostics for life science research and manufactures proprietary products. Cell Sciences drives the sales, marketing and distribution for biomedical products. In Jan 2004, the company launched a patented 3-D growth scaffold and the market’s first disposable cell culture spinner systems.
Cell Sciences markets products targeting an extensive customer base comprising laboratories (research, clinical and bioprocessing), industry (biopharmaceuticals), specialists and hospitals. The company focuses on product lines core to the strategic business of the CyGenics Group in areas of stem cell biotechnology and regenerative medicines, as well as products that add to a more comprehensive offering to the customers we serve. Visit us at www.cygenics.com/cellsciences
About CyGenics
CyGenics is a cell therapy company focused on the development and commercialisation of adult stem cell-related technologies and applications into therapeutic products and services. From its headquarters in Australia, CyGenics operates four subsidiary businesses: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), Cytomatrix (cell therapeutics and technology development) based in the USA, and CytoVations (new product development) also based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com
About Acacia Research Corporation
Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.
The CombiMatrix group is developing a platform technology to rapidly produce customisable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix’s group’s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 33 patent portfolios, which include over 120 US patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modelling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.
Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com
For more information, please contact:
General Inquiries Steven Fang, CEO, CyGenics Ltd Mob: +61 (0)400 933 243 Email: steven.fang@cygenics.com Ian Brown, COO, CyGenics Ltd Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com
Media Inquiries Rebecca Piercy, Buchan Consulting Ph: +61 (0)3 9866 4722 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au Ronald Hee, CyGenics Ltd Ph: +65 6238 0808 Mob: +65 9061 9098 Email: ronald.hee@cygenics.com
Bret L. Undem, Acacia Research Media Relations Tel. (425) 493-2293 Fax. (425) 493-2010
